Emotional adjustment in adults with chronic migraine treated with anti-CGRP antibodies
Studies how adults with chronic migraine cope emotionally while on anti-CGRP treatment.
Key facts
- Who runs it
- Central Hospital, Nancy, France
- Where
- Nancy, FranceSee the site
- Trial code
- Registry title
- Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal Antibodies
- Status
- Not yet recruiting
- People taking part
- 30 people, planned
- Started
- Oct 2026
- Planned end
- Oct 2026
- Type of study
- Observational, 2 groups
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic migraine who are treated with an anti-CGRP monoclonal antibody at the CHRU de Nancy and who completed the first psychological interview.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Chronic migraine diagnosed by a neurologist
- Earlier treatment
- Treated with an anti-CGRP monoclonal antibody given at the CHRU de Nancy
Main reasons for not taking part
- No completed initial psychological interview
- No analyzable clinical and psychological data
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- • Diagnosis of chronic migraine established by a neurologist; Treatment with an anti-CGRP monoclonal antibody administered at the CHRU de Nancy; Completion of the initial psychological interview; Availability of analyzable clinical and psychological data
Who cannot take part
- -
Where in France
- CHRUNancy, FranceContact: laure barbe, clinical psychologistNo longer taking part
About the trial
What the trial wants to find out
Chronic migraine is a disabling neurological condition that can significantly affect quality of life, emotional well-being, social participation, and daily functioning. Although anti-CGRP monoclonal antibodies have substantially improved migraine management for many patients, little is known about the psychological experiences and adjustment processes associated with these treatments.
Read full original descriptionShow less
This observational study aims to explore the psychological adaptation of adults with chronic migraine treated with anti-CGRP monoclonal antibodies. Participants will complete standardized questionnaires assessing migraine-related disability, headache impact, anxiety and depressive symptoms, quality of life, and treatment experiences at treatment initiation and after 12 months of follow-up. Psychological interviews will also be conducted to explore patients' perceptions, coping strategies, and lived experiences of treatment.
The study seeks to identify factors associated with positive or negative psychological adaptation to treatment and to better understand patients' emotional experiences throughout their care pathway. The findings may contribute to the development of tailored psychological support interventions for individuals living with chronic migraine.
The 2 groups in the trial
- Marked Improvement Group Patients showing a highly favorable response to anti-CGRP treatment.
- No Perceived Efficacy Group Patients reporting no perceived efficacy following anti-CGRP treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Psychological Adjustment Following Extreme Therapeutic Responses to Anti-Calcitonin Gene-Related Peptide (CGRP) Treatment in Patients With Chronic Migraine: A Mixed Quantitative and Qualitative Study
- Plain-language title
- Emotional adjustment in adults with chronic migraine treated with anti-CGRP antibodiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 16 October 2026